VRPX
Virpax Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.00
+0.00%Price chart
Sep 17Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16
Key dataOct 16, 2026
Open$0.02
From 52W high−99.48%
Volume51.00
Market cap$3403.52
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 16, 2026
Open
$0.02
From 52W high
−99.48%
Volume
51.00
Market cap
$3403.52
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.4x
P/E (TTM)
—
RSI (14)
47.2
MomentumView details →
1D Return
+0.00%
YTD Return
−92.73%
SummaryUpdated Dec 1, 2024
Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) is a preclinical-stage pharmaceutical company founded in 2016 and headquartered in Berwyn, Pennsylvania. The company went public in February 2021 and focuses on developing innovative drug-delivery systems and drug-releasing technologies for non-opioid pain management and central nervous system disorders. Since its founding, Virpax has been working to address the ongoing opioid crisis by creating alternative pain management solutions that avoid the addictive properties of traditional opioid medications.
Similar companies
Latest newsMore news →
No recent news for VRPX.